Analysts Offer Predictions for Globus Medical Q1 Earnings

Globus Medical, Inc. (NYSE:GMED) – Stock analysts at Zacks Research lifted their Q1 2028 earnings per share (EPS) estimates for shares of Globus Medical in a research note issued on Tuesday, March 31st. Zacks Research analyst Team now expects that the medical device company will post earnings per share of $1.20 for the quarter, up from their previous forecast of $1.19. Zacks Research currently has a “Strong-Buy” rating on the stock. The consensus estimate for Globus Medical’s current full-year earnings is $3.44 per share.

Globus Medical (NYSE:GMED) last posted its quarterly earnings data on Tuesday, February 24th. The medical device company reported $1.28 earnings per share for the quarter, topping the consensus estimate of $1.06 by $0.22. Globus Medical had a return on equity of 12.57% and a net margin of 18.30%.The company had revenue of $826.42 million during the quarter, compared to analysts’ expectations of $803.29 million. During the same period in the prior year, the firm earned $0.84 earnings per share. Globus Medical’s revenue for the quarter was up 25.7% compared to the same quarter last year.

A number of other analysts also recently issued reports on the stock. Barclays boosted their price objective on shares of Globus Medical from $118.00 to $123.00 and gave the stock an “overweight” rating in a research report on Wednesday, February 25th. Canaccord Genuity Group boosted their price target on shares of Globus Medical from $105.00 to $112.00 and gave the stock a “buy” rating in a research report on Friday, January 9th. Royal Bank Of Canada increased their price objective on shares of Globus Medical from $92.00 to $100.00 and gave the stock an “outperform” rating in a research note on Wednesday, December 17th. Citigroup restated a “market perform” rating on shares of Globus Medical in a report on Thursday, January 8th. Finally, Truist Financial set a $115.00 target price on Globus Medical in a research report on Wednesday, February 25th. Three equities research analysts have rated the stock with a Strong Buy rating, eight have given a Buy rating and five have given a Hold rating to the company’s stock. Based on data from MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and a consensus target price of $104.36.

Globus Medical Stock Up 1.9%

NYSE:GMED opened at $87.82 on Thursday. Globus Medical has a twelve month low of $51.79 and a twelve month high of $101.40. The business has a 50 day moving average price of $89.02 and a two-hundred day moving average price of $80.76. The company has a market cap of $11.88 billion, a P/E ratio of 22.29, a price-to-earnings-growth ratio of 2.01 and a beta of 1.09.

Institutional Trading of Globus Medical

A number of hedge funds have recently made changes to their positions in the business. SBI Securities Co. Ltd. increased its holdings in shares of Globus Medical by 98.2% during the 4th quarter. SBI Securities Co. Ltd. now owns 337 shares of the medical device company’s stock worth $29,000 after acquiring an additional 167 shares during the last quarter. Advisory Services Network LLC acquired a new stake in Globus Medical during the 3rd quarter valued at $26,000. EverSource Wealth Advisors LLC boosted its position in Globus Medical by 74.3% during the second quarter. EverSource Wealth Advisors LLC now owns 462 shares of the medical device company’s stock worth $27,000 after purchasing an additional 197 shares during the period. Advisors Asset Management Inc. acquired a new position in shares of Globus Medical in the second quarter valued at $28,000. Finally, Larson Financial Group LLC raised its position in shares of Globus Medical by 83.4% in the fourth quarter. Larson Financial Group LLC now owns 532 shares of the medical device company’s stock valued at $46,000 after purchasing an additional 242 shares during the period. 95.16% of the stock is owned by institutional investors and hedge funds.

Insiders Place Their Bets

In other Globus Medical news, CFO Kyle Kline sold 3,594 shares of the stock in a transaction on Thursday, January 8th. The shares were sold at an average price of $101.10, for a total value of $363,353.40. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this link. Also, Director Leslie V. Norwalk sold 2,000 shares of the company’s stock in a transaction dated Thursday, January 8th. The shares were sold at an average price of $101.10, for a total transaction of $202,200.00. Following the completion of the sale, the director directly owned 10,419 shares in the company, valued at approximately $1,053,360.90. The trade was a 16.10% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Over the last three months, insiders have sold 35,594 shares of company stock valued at $3,332,253. 18.51% of the stock is currently owned by corporate insiders.

Globus Medical News Summary

Here are the key news stories impacting Globus Medical this week:

• Positive Sentiment: Zacks Research raised EPS estimates across multiple quarters and fiscal years (small upward tweaks to Q1/Q2/Q3 2026–2028 and FY2026–FY2028) and kept a “Strong‑Buy” rating — signaling improving analyst confidence in Globus’s growth trajectory. Article Title
• Positive Sentiment: Recent fundamental momentum supports the upgrades: Globus beat latest quarterly revenue and EPS estimates and reported double‑digit revenue growth year‑over‑year, reinforcing the bullish analyst revisions. Article Title

About Globus Medical

Globus Medical, Inc (NYSE:GMED) is a leading medical device company specializing in musculoskeletal solutions for spine and orthopaedic applications. Founded in 2003 by David C. Paul and headquartered in Audubon, Pennsylvania, the company develops, manufactures and markets implantable devices and surgical instruments designed to treat spinal disorders and promote bone healing. Its product portfolio encompasses solutions for minimally invasive and open surgical procedures, including interbody fusion devices, pedicle screw systems, and biologics used to enhance fusion outcomes.

In addition to its core spine business, Globus Medical has expanded into robotics and navigation systems to support precision and efficiency in the operating room.